Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
September 4, 2019

Non-Hodgkin’s lymphoma novel pipeline is diverse and dominated by combination therapies

Combination therapies are the norm in non-Hodgkin’s lymphoma treatment, and the pipeline reflects that.

The late-stage pipeline for non-Hodgkin’s lymphoma (NHL) contains a diverse range of mechanisms of action. 

Non-Hodgkin’s lymphoma treatment

The figure below displays ongoing trials for agents seeking a first approval in NHL. Of the seven therapies, two are targeting CD19 (Celgene’s lisocabtagene maraleucel and MorphoSys’ tafasitamab) while the remaining five each work against different targets. 

Combination therapies are the norm in NHL treatment, and the pipeline reflects that as lisocabtagene maraleucel and Amgen’s Blincyto are the only therapies being investigated as monotherapies, while the remainder is being investigated in combination with other therapies. 

Roche’s Polivy (polatuzumab vedotin-piiq) was recently approved by the US Food and Drug Administration (FDA), in June 2019, in combination with bendamustine and rituximab. GlobalData believes TG Therapeutics’ U2 regimen (ublituximab + umbralisib) will be the next therapy to achieve an FDA approval, in 2020.

 Source: GlobalData © GlobalData

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

CMR = complete metabolic response; DLT =dose-limiting toxicities ; EFS = event-free survival; ORR = overall response rate; OS = overall survival; PCD = primary completion date; PFS = progression-free survival; TLS = tumor lysis syndrome

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy